Changes in the molecular profiles of large-vessel vasculitis treated with biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors

Giant cell arteritis and Takayasu arteritis are two types of primary large-vessel vasculitis (LVV). Although glucocorticoids (GC) are the standard treatment for LVV, the disease relapse rates are high. Recent clinical trials on biological disease-modifying anti-rheumatic drugs (bDMARDs) and Janus ki...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Kotaro, Suzuki, Katsuya, Takeshita, Masaru, Takeuchi, Tsutomu, Kaneko, Yuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183585/
https://www.ncbi.nlm.nih.gov/pubmed/37197652
http://dx.doi.org/10.3389/fimmu.2023.1197342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183585/
https://www.ncbi.nlm.nih.gov/pubmed/37197652
http://dx.doi.org/10.3389/fimmu.2023.1197342

Ejemplares similares